| Title |
Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, December 2013
|
| DOI | 10.2147/ndt.s54051 |
| Pubmed ID | |
| Authors |
Nagahide Takahashi, Masayoshi Takahashi, Takayuki Saito, Misuzu Iizumi, Yuki Saito, Hiroko Shimizu, Taka Matsumura |
| Abstract |
This 13-week, double-blind study was conducted to confirm the efficacy and safety of paliperidone palmitate (PP), at dosing regimens approved in other countries, in Asian patients with schizophrenia. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 74 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 19% |
| Student > Bachelor | 9 | 12% |
| Researcher | 9 | 12% |
| Other | 7 | 9% |
| Student > Ph. D. Student | 6 | 8% |
| Other | 12 | 16% |
| Unknown | 17 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 30% |
| Neuroscience | 7 | 9% |
| Nursing and Health Professions | 6 | 8% |
| Psychology | 6 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Other | 8 | 11% |
| Unknown | 20 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2013.
All research outputs
#17,285,668
of 25,373,627 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,902
of 3,132 outputs
Outputs of similar age
#205,368
of 320,965 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#31
of 53 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,965 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.